Table 1 Participant demographics

Sex, n (%)

 Female

374 (64.6)

 Male

205 (35.4)

Age, years, n (%)^a

(N = 577)

 Pediatric

360 (62.4)

  < 1

5 (0.9)

  1 to < 5

68 (11.8)

  5 to < 12

165 (28.6)

  12 to < 18

122 (21.1)

 Adult

217 (37.6)

  18 to < 30

56 (9.7)

  30 to < 50

96 (16.6)

  ≥ 50

65 (11.3)

Age at enrolment, years, mean (SD) [median]

 Overall

21.7 (18.7) [13.6]

  Pediatric

9.5 (4.5) [9.9]

  Adult

41.9 (15.5) [41.1]

Race, n (%)^a

(N = 577)

 White

374 (64.8)

 Black or African American

11 (1.9)

 Asian

6 (1.0)

 American Indian or Alaska Native

1 (0.2)

 Not applicable/not collected as per local regulations

143 (24.8)

 Unknown

27 (4.7)

 Other

15 (2.6)

Country, n participants enrolled (sites enrolled)

 Belgium

6 (4)

 Bulgaria

0 (2)

 Denmark

12 (5)

 France

141 (7)

 Germany^b

46 (1)

 Ireland

1 (1)

 Israel

0 (2)

 Italy

36 (10)

 The Netherlands^c

18 (1)

 Norway

6 (3)

 Portugal

4 (5)

 Slovakia

0 (1)

 Slovenia

2 (1)

 Spain

38 (10)

 Sweden

35 (3)

 United Kingdom

234 (21)

Treatment distribution at baseline, n (%)^a,d

Pediatric

(N = 360)

Adult

(N = 217)

 Burosumab

165 (45.8)

13 (6.0)

 Conventional therapy only

114 (31.7)

99 (45.6)

 Untreated

2 (0.6)

6 (2.8)

 Not reported

79 (21.9)

99 (45.6)